Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer

Published:2013-09 Issue:3 Volume:81 Page:462-467
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Tran Thang N.,Selinger Christina I.,Kohonen-Corish Maija R.J.,McCaughan Brian C.,Kennedy Catherine W.,O’Toole Sandra A.,Cooper Wendy A.

Funder

The Sydney Foundation for Medical Research

Cancer Institute NSW, Sydney Breast Cancer Foundation

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. New driver mutations in non-small-cell lung cancer;Pao;Lancet Oncol,2011

2. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements;Cooper;Pathology,2011

3. Molecular origins of lung cancer: prospects for personalized prevention and therapy;Haura;J Thorac Oncol,2010

4. Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma;Yip;J Thorac Oncol,2013

5. Comprehensive genomic characterization of squamous cell lung cancers;Hammerman;Nature,2012

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FGFR and inhibitors;Fibroblast Growth Factors;2024

2. Flavonoids as receptor tyrosine kinase inhibitors in lung cancer;Journal of Functional Foods;2023-11

3. Prognostic value of perineural invasion in resected non-small cell lung cancer: A meta-analysis;Heliyon;2023-04

4. Benzimidazole‐based protein kinase inhibitors: Current perspectives in targeted cancer therapy;Chemical Biology & Drug Design;2022-08-19

5. Understanding the Molecular Kinetics in NSCLC Through Computational Method;Systems Biomedicine Approaches in Cancer Research;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3